New drug trial aims to tame Hard-to-Treat cancers
NCT ID NCT07369505
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This early-phase study tests a new drug called Sapu003 in 27 adults with advanced solid tumors (like breast, kidney, or liver cancer) that are sensitive to mTOR-targeted therapy. The main goal is to find the safest dose and check for side effects. Participants receive Sapu003 weekly by IV, sometimes with another drug (exemestane). This is not a cure—it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SOCRU
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.